Literature DB >> 18542905

[Multimodal treatment of adult attention-deficit hyperactivity disorder].

C P Jacob1, A Philipsen, D Ebert, J Deckert.   

Abstract

The indication for treatment of adult attention-deficit hyperactivity disorder (adult ADHD) is derived not from the diagnosis itself but results from the severity of symptoms, comorbidities, psychosocial consequences, and a lack of defined resources for ADHD. The basis of therapy is psychoeducation that includes teaching about symptoms, models of the disorder, and options for treatment. The combination of pharmacotherapy and psychotherapy is recommended. Methylphenidate is considered the first-line therapy, because of its strong effect and modest side effects, but is not authorized in Germany ("off-label use"). Atomoxetine, which is authorized for continuing treatment into adulthood, is indicated if methylphenidate is insufficient or has unacceptable side effects and in case of comorbid substance use. Various psychotherapeutic interventions using available ADHD-typical resources have demonstrated positive effects. Psychosocial support and self-help groups complete the treatment concept. Persistence of the treatment indication has to be reevaluated at regular intervals. Disorder-specific multimodal therapy of adult ADHD conforms to the complex, primarily neurobiologic etiology and the psychosocial consequences.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18542905     DOI: 10.1007/s00115-008-2510-6

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  25 in total

1.  A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  1999-12

2.  The Wuerzburg Research Initiative on Adult Attention-Deficit/Hyperactivity Disorder (WURIN-AADHD): multi-layered evaluation of long-term course.

Authors:  Christian Jacob; Klaus-Peter Lesch
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-09       Impact factor: 5.270

3.  Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD.

Authors:  Joseph Biederman; Thomas J Spencer; Timothy E Wilens; Richard H Weisler; Stephanie C Read; Simon J Tulloch
Journal:  CNS Spectr       Date:  2005-12       Impact factor: 3.790

4.  Co-morbidity of adult attention-deficit/hyperactivity disorder with focus on personality traits and related disorders in a tertiary referral center.

Authors:  Christian P Jacob; Jasmin Romanos; Astrid Dempfle; Monika Heine; Christine Windemuth-Kieselbach; Anja Kruse; Andreas Reif; Susanne Walitza; Marcel Romanos; Alexander Strobel; Burkhard Brocke; Helmut Schäfer; Armin Schmidtke; Jobst Böning; Klaus-Peter Lesch
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-04-01       Impact factor: 5.270

5.  Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study.

Authors:  Timothy E Wilens; Barbara R Haight; Joseph P Horrigan; James J Hudziak; Norman E Rosenthal; Daniel F Connor; Kenneth D Hampton; Nathalie E Richard; Jack G Modell
Journal:  Biol Psychiatry       Date:  2005-04-01       Impact factor: 13.382

6.  A cognitive remediation programme for adults with Attention Deficit Hyperactivity Disorder.

Authors:  Caroline S Stevenson; Stephanie Whitmont; Laurel Bornholt; David Livesey; Richard J Stevenson
Journal:  Aust N Z J Psychiatry       Date:  2002-10       Impact factor: 5.744

7.  Structured group psychotherapy in adults with attention deficit hyperactivity disorder: results of an open multicentre study.

Authors:  Alexandra Philipsen; Harald Richter; Julia Peters; Barbara Alm; Esther Sobanski; Michael Colla; Mirka Münzebrock; Corinna Scheel; Christian Jacob; Evgeniy Perlov; Ludger Tebartz van Elst; Bernd Hesslinger
Journal:  J Nerv Ment Dis       Date:  2007-12       Impact factor: 2.254

8.  Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies.

Authors:  David Michelson; Lenard Adler; Thomas Spencer; Frederick W Reimherr; Scott A West; Albert J Allen; Douglas Kelsey; Joachim Wernicke; Anthony Dietrich; Denái Milton
Journal:  Biol Psychiatry       Date:  2003-01-15       Impact factor: 13.382

9.  Attention-deficit hyperactivity disorder as a potentially aggravating factor in borderline personality disorder.

Authors:  Alexandra Philipsen; Matthias F Limberger; Klaus Lieb; Bernd Feige; Nikolaus Kleindienst; Ulrich Ebner-Priemer; Johanna Barth; Christian Schmahl; Martin Bohus
Journal:  Br J Psychiatry       Date:  2008-02       Impact factor: 9.319

10.  Acute effects of methylphenidate on neuropsychological parameters in adults with ADHD: possible relevance for therapy.

Authors:  J C Kurscheidt; P Peiler; A Behnken; S Abel; A Pedersen; T Suslow; J Deckert
Journal:  J Neural Transm (Vienna)       Date:  2008-02-12       Impact factor: 3.575

View more
  4 in total

Review 1.  [Forensic psychiatry in the era of neuroscience: present status and outlook for neurobiological research].

Authors:  J L Müller
Journal:  Nervenarzt       Date:  2009-03       Impact factor: 1.214

2.  [The health economics of attention deficit hyperactivity disorder in Germany. Part 2: Therapeutic options and their cost-effectiveness].

Authors:  M Schlander; G-E Trott; O Schwarz
Journal:  Nervenarzt       Date:  2010-03       Impact factor: 1.214

Review 3.  [Comorbidity of substance use disorders and attention-deficit hyperactivity disorders: pathogenesis and therapy].

Authors:  A J Fallgatter; C P Jacob
Journal:  Nervenarzt       Date:  2009-09       Impact factor: 1.214

Review 4.  The impact of psychological theory on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults: A scoping review.

Authors:  Rebecca E Champ; Marios Adamou; Barry Tolchard
Journal:  PLoS One       Date:  2021-12-21       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.